PTO/58/08A (10-01)
Approved for use through 1001/2002. OMB 0651-0031
U.S. Patent and Tredemark Office: U.S. DEPARTMENT OF COMMERCE
ix Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Complet If Kn wn Substitute for form 1448A/PTO Application Number 10/684,740 INFORMATION DISCLOSURE Filing Date October 14, 2003 STATEMENT BY APPLICANT First Named Inventor Shalini Sharma 1824 Inu hA (use as many sheets as necessary) Sudhaker Patel Examiner Name 01 10 Attorney Docket Number 18015-D3 Sheet 1

	U.S. PATENT DOCUMENTS							
Examiner Initials		Datument Number Number - Kind Code* (# known	Publication Date MM-DD-YYYY	Name of Patentae or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Rolevant Figures Appear			
K	<u> </u>	US- 4,845,231	07-04-1989	Kees				
1	<u>Ł</u>	US- 5,948,803	09-07-1999	Maeda, et al.				
122	\leq	ug: 5817693 (abstract)	10-6-1998	Cousins et al	. —			
		US-4011321 (abstract)	3-8-1997	Coates et al	<u> </u>			
		US-						
		US-						
	<u> ``</u>	U9-						
	<u> </u>	US-		<u> </u>	· ·			
		US-						
<u> </u>	<u> </u>	UB-						
ļ	<u></u>	US-		<u> </u>				
<u> </u>	<u> </u>	US-						
<u> </u>		US-		<u> </u>				
<u> </u>		US-						
<u> </u>		US-						
	 	UŞ-						
l	-	US-						
	 -	US-		<u> </u>				
	 -	U8-	<u> </u>					
	L	US		l	L			

		FOR	EIGN PATENT D	OCUMENTS		
Examiner Initials	Cito Cito	Foreign Patent Document Control Code Warning	Publication Date MM-DD-YYYY	Name of Palentee or Applicant of Cited Decument	Pagas, Calumns, Unes, Where Raisvani Passages or Raisvani Figures Appear	78
		WO 02/59077 (abstract)	:08/2002			
4	·	WO 02/14291 (abstract)	02/2002	. —		1
		WO 02/02119 (abstract)	01/2002			=
		WO 01/81340 (abstract)	11/2001			
127	_	BR 9802163 (abstract)	11 /2000.			\equiv
X		JP 01/181281 (abstract)	07/1989-	-		\equiv
	<u> </u>	WO 00/23409 (abstract)	0412000	. —		
X		WO 99/62520 (abstract)	12/1999			E
100		WO 98/25608 (abstract)	0611998-		÷	
L X	L	JP 10130241 (abstract)	0511998			-

Examiner Signature	-d b-d b-	BAL	Oale Considered	5/4/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Oraw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicants unique citation designation number (optional). 2 See Kinde Codes of USPTO Petent Occuments at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent document, be indication of the year of the retign of the Emperor must precede the sariel number of the potant document. 8 Kinde document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 If possible. 8 Applicant is to place a check mark here if English language Translation is stached.

Englant tanguage Pransation to statistics.

Burden Hour Statement: This form is estimated to take 2.0 hours to complate. Time will vary depending upon the needs of the Individual case.

Any comments on the amount of time you are required to complate this form should be sent to the Chief Information Officer, U.S. Patent and
Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant
Commissioner for Patents, Washington, OC 20231.



PTO/SBIBBA (10-01)
Approved for use through 19/31/2072. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act at 1895, no persons are required to respond to a collection of Information unless it contains a valid OMB

Substitute for form 1448A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 01 10

C.	mpl t If Kn wn
Application Number	10/684,740
Filing Date	October 14, 2003
First Named Inventor	Shalini Sharma
Art Unit	1624_
Examiner Name	Sudhaker Palel
Attorney Docket Number	18015-D3

	 	U.S. PAT	NT DOCUMENTS	
Examino Initiala	Document Number Number - What Code (Il know	Publication Date	Name of Palantes or Applicant of Clind Document	Pages, Columns, Lines, Where Relovant Passages or Relovant Flauras Acrear
	 US.	•		
	US-			•
	US-			
	US-	•		
	US-			
	 US-	•		
· ·	US-			
	U\$-			
	UŞ			
	US.			
	US.			·
	US-			
	US-			

		EOD!	IGN PATENT D	OCHAENIVE		_
Examiner Inligite	Cito Ma. 1	Foreign Palent Decrement Course Code 9 Institute Code 9 Institute Code 10 Institute	Publication Dato	Name of Palanteo or Applicant of Cited Occument	Pogos, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	10
		WO 98/08836 (abstract)	03/1998	-	*	=
1		WO 95/13262 (abstract)	05/1995	•		=
		WO 94/27993 (abstract)	12/1994		_	=
100		WO 93/08799 (abstract)	U611993 ·		~	-
42	Ĭ	JP 04159266 (abstract)	06/1992 -			-
3		EP 407891 (abstract)	01/1991-			=
	_	EP 393400 (abstract)	10 11990 -		~ ~	=
9		JP 01063570 (abstract)	03/1989-			=
00		WO 88/08418 (abstract)	11 11988 -	<i></i>		三
10		EP 288190 (abstract)	10 11988			•

Examiner Signature Considered 5/4/CD					
Signature Considered 5/4/04	Everyland 01			- 1.	1
Signature	Charminer //		Date !	5 /	/ rn_ ·
	Signature		Canaldanad	U / 4	, 09
	Coldinatora		.Constitue [//	,

Burdon How Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any commonts on the emount of time you are required to complete this form should be sent to the Chlof Information Officer, U.S. Potent and Trademerk Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Potents, Washington, DC 20231.

^{*}EXAMINER: billet if reference considered, whether or not clintion is in conformance with MPEP 809. Order the through citation if not in conformance and not considered. Include copy of this form with nost communication to applicant.

*Applicant's unique citation designation number (optional). *Soo kinds Codes of USPTO Patent Documents at www.uspto.new or MPEP 901,04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the relign of the Emporer must proceed the sortial number of the patent document. *S Kind of document by the appropriate symbols on Indication on the document under WIPO Standard ST. 16 if possible. *O Applicant to to place a check mark here if English briguege Translation to stacked.



PTO/SB/BBA (10-01)
Approved for use through 10/31/2002. OMB 0461-0031
U.S. Patent and Trademark Office: U.S. OEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB
control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

01 10

Sheet 3

Co	mpi t if Known '
Application Number	10/684,740
	October 14, 2003
First Named Inventor	Shalini Sharma
Art Unit	1624
Examiner Name	Sudhaker Patel
Attorney Docket Number	18015-D3

			U.S. PATE	NT DOCUMENTS	
Examiner faillats	Cile No.1	Corsument Mumber Number- Kind Code [®] (II keews	Publication Date	Name of Palantas or Applicant of Cited Document	Pages, Columns, Unes, Where Relevant Pessages or Relevant Floures Appear
		US-			
		US-		·	
		US-			· · · · · · · · · · · · · · · · · · ·
		US-	·		
		US:			
		.US-	·	<u> </u>	
		U3-			
		US-			
		US-			
		us.		·	
		US-			
		US-			•
		บระ			•
	1	US-			
		US-			
		US-			
	Т	U9-			
	T -	US-			
r	1	US-			
	1	US-			

		FORE	IGN PATENT D	OCUMENTS		
Examiner Initials	Cite No.1	Foreign Patent Document Courty Code 3 Mumber - Mad Code 3 Missource	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Linea, Where Relevant Passages or Retovent Figures Appear	τ,
		JP 61040270 (abstract)	02/1986			-1
	-	JP 55015460 (abstract)	02/1980			_{
100		GB 1488330 (abstract)	10/1977_		~	3
X		JP 52025734 (abstract)	02/1911			
1		DE 2527066 (abstract)	01 11976			=
1		DE 2459468 (abstract)	07/1975			_
000	_	FR 2191887 : (abstract)	111974			=
N.		JP 47025149 (abstract)	ــــــــــــــــــــــــــــــــــــــ			
X		JP 56115747 (abstract)	1/1981	<u> </u>		
	<u> </u>	DE 3012012 (abstract)	10/1981-			

Date Examiner Considered

^{*}EXAMINER: Initial it reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in

^{*}EXAMINER: Initial if reference considered, whether or not claifents in conformance with MPEP 609. Oraw line through cliniton if not in conformance and not considered, include copy of this form with next communication to applicant.

1 Applicants unique citation distinction number (optional), 2 See Minds Codes of USPTO Patent Documents at https://www.uspto.gov or MPEP 901.04.

2 Enter Office that issued the document, by the two-failer code (MIPO Standard ST.3).

4 For Japenasa patent documents, the indication of the year of the reign of the Emperor must present the sertal number of the patent document.

5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST, 18 II possible.

6 Applicant to bridge a check mark here if English tanguage Translation is attached.

6 Burdon Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary dopending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Office, U.S. Patent and Tradamerk Office, Westington, OC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Potents. Westington, OC 20231.



PTO/SB/08A (10-01)
Approved for use through 10/31/2002. GMB 0531-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information units 8 contains a valid OMB control number. control number.

Substitute	for form 1449A/PTO		· Co	mplets if Known	
			Application Number	10/884,740	
INFO	RMATION D	ISCLOSURE	Filing Oate	October 14, 2003	
STAT	STATEMENT BY APPLICANT		First Named Inventor	Shalini Sharma	
	•		Art Unit	1624	
(4	ise es many sheels	as necessary)	Examiner Name	Sudhaker Patel	
Sheet	01	10	Attorney Docket Number	18015-D3	

	U.S. PATENT DOCUMENTS						
Examiner InWeis		Oncement Number Number - Kind Code* (II know	Publication Date	Name of Patentse or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Fixures Appear		
	_	US-					
		U8-					
		U\$-					
		US-					
		US					
		U5-					
		US-					
		Ù\$-					
		us.					
		US-					
		US-					
		U\$-					
		us.		•			
		US-					
		US-			•		
		US.			·_		
		บระ					
		นร		······	,		
		US-					
		US-	*****				

	FOREIGN PATENT DOCUMENTS						
Exeminer Initials		Foreign Patent Document Courty Dock - Number - Sind Code ((Factor)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appoar	T4	
12		JP 50014653 (abstract)	02/1475	,			
		DE 2512673 (abstract)	10/1975			=	
		DE 1929165 (abstract)	06 4969			7	
1		ZA 6705655 (abstract)	01 / 190-7- 08-21-1997			=	
200	_	WO 97/30017	08-21-1997	Shinkal, et al.			
200	_	WO 98/07681	02-26-1998	Moinet, et al.		1	
100		WO 99/62520	12-09-1898	Young, et al.		Ξ	
4		EP 71399	02-09-1983	Tsung, et al.		•	
FF		WO 92/12123	07-23-1992	Schirlin, et al.		-	
	1	WO 00/83161	10-26-2000	Kolb, et al.		_	

Examiner Signature	pod	h, L	B/A	Date Considered	5/4	ory

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw fine through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional).

*See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

**Senter Office that leaved the document, by the two-tester code (MIPO Standard ST.).

*For Japanese patent documents, the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

*Applicant is to place a check mark here if English language Transistion is attached.

Burdon Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief information Officer, U.S. Patent and Tradement Officer, Washington, OC 2023. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Petents, Washington, OC 20231.

PTO/SBI08B (10-01)
Approved for use through 10/31/2002. ONB 0651-0031
U.S. Patent and Tredemark Office: U.S. DEPARTMENT OF COMMERCE
Unter the Paperwork Reduction Act of 1995, no persons are required to respend to a collection of information unless it contains a valid OMB control number.

Compl to If Kn wn Substitute for form 1449B/PTO 10/884,740 Application Number INFORMATION DISCLOSURE October 14, 2003 Filing Onto Shalini Sharma First Named Inventor STATEMENT BY APPLICANT 1624 Group Art Unit Sudhaker Patel (use as many sheets as necessary) Examiner Name Sheet 5 of 10 Attorney Docket Number 18015-03

		NON PATENT PUBLICATIONS	
Examinar Initials	Cits No. 1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the flow (book, magnathe, journal, sorial, symposium, catalog, etc.), date, page(s), volume-bases number(s), outlished, published city and/or country where numbers are	72
Eng	7	Karche, et al., "Electronic Effects in Migratory Groups", Journal of Organic Chemistry, Vol. 68, No. 19, pages 6323-6332, 2001. (Abstract)	_
13x		Poupardin, et al.,"First approach to the cycloisodityrosine unit of RA-IV", Tetrahedron Letters, Vol. 42, No. 6, pages 1523-1526, 2001. (Abstract)	-
bo	-	Manthey, et al., "Synthesis of Human Ultraviolet Filter Compounds:", Journal of Organic Chemistry, Vol. 64, No. 11, pages 3930-3933, 1999. (Abstract)	-
m		Wu, et al., "Improvement on the preparation of .betaketo esters", Huaxue Shiji, Vol. 20, No. 6, pages 376-377, 1988. (Abstract)	-
8		Wu, el al., "Total syntheses of furogusiacin and related analogs", Huaxua Yanjiu Yu Yingyourig, Vol. 9, No. 6, pages 595-599, 1997. (Abstract)	-
Do	-	Fadnavis, et al., "Baker's yesst modisted enantiospecific synthesis of enti-(2R,3R)", Tetrahedron: Asymmetry, Vol. 8, No. 24, pages 4003-4006, 1997. (Abstract)	
frac		Wu, et al.; "A modification of the Knorr exidative coupling method for preparation of 1,4-dikelones", Synthetic Communications, Vol. 27, No. 2, pages 331-338, 1997. (Abstract)	-
Par		Girard, et al. "Syntheses of the syn and anti .alphaaminobetahydroxy acid of vancomycin", Tetrahedron Letters, Vol. 37, No. 44, pages 7867-7970, 1886. (Abstract)	-
Co		Smith, et al., "Synthesis and PAF aniagonist activity of some 2,5-diaryltetrahydrofurans incorporating PAF-like functional groups", European Journal of Medicinal Chemistry, Vol. 31, No. 5, pages 347-358, 1998. (Abstract)	/
Tro		Maruyama, et al., "A synthesis of (.+.)-pinoresinol and its related compound using potassium persultate (K2S208) oxidation of benzoylacetates", Heterocycles, Vol. 37, No. 2, pages 839-845, 1994. (Abstract)	-
Esp		Reo, et al., "Studies on cyclodepsipeptides. Part II. The total synthesis of jaspamide and geodiamolide-D", Tetrahedron Letters, Vol. 34, No. 44, pages 7085-7088, 1993. (Abstract)	

Date Considered

^{*}EXAMINER: Initial If reference considered, whether or not cliation is in conformance with MPEP 809. Onew line through cliation it not in confor and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement; This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any commants on this amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademerk Office, Washington, DC 20231. OO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/038 (10-01)
Approved for use through 10/31/20/2 OMB 6551-0331
U.S. Petant and Tredement Office; U.S. DEPARTMENT OF COMMERCE
rock Reduction Act of 1985, no persons are required to respond to a callection of information unless a cardians o valed OMB

Substituto for form 1449BIPTO	Gempl & If Kn wn
	Application Number 10/884,740
information disclosuri	Fillne Tate October 14, 2003
Statement by applican	First Named Inventor Shalini Sharma
	Group Art Unit 1624
(use as many sheats as necessary)	Examiner Name Sudhafter Patel
Sheet 6 of 10	Alterney Docket Number 18015-D3

		NON PATENT PUBLICATIONS	
Examiner Initiate	Cão No. 1	traivide name of the outher (in CAPITAL LETTERS), title of the article (when oppropriate), 600 of the item (book, magazine, journal, cerial, symposium, estates, etc.), date, page(a), volumo-issue aumberta), mhilsher, city and inc. comby where no hillsher is a number of the article and included in the comby where no hillsher is a number of the article and the comby where no hillsher is a number of the comby where no hillsher is a number of the comby where no hillsher is a number of the comby where no hillsher is a number of the comby where no hillsher is a number of the comby where no hillsher is a number of the comby where number of the comby where the comby whe	[1,
Mar		Colotta, et al., "Tricyclic heteroaromatic systems", Farmaco, Vol. 48, No. 10, pages 1139-1154, 1991. (Abstract)	
gra	7	Dillard, et st., "(Phenylmothoxy) phenyl derivatives of w-oxo- and w-tetrozolytalhanoic acids", J. Med. Chem., Vol. 34, No. 9, pages 2768-2779, 1991. (Abstrect)	1
200		Bose, et al., "Synthesis of 4-phenylcoumarins from Dalbergia volubilis and Exostema caribaeum", Phytochemistry, Vol. 30, No. 7, pages 2438-2439, 1891. (Abstract)	
6		Bose, et al., "Synthesis of 4-phanylcoumarins", Indian J. Chern., Sect. B. Vol. 288, No. 5. pages 422- 444, 1990. (Abstract)	
Sug-		Colotta, el al., "Tricyclic heteroaromalic systems", J. Med. Chem., Vol. 33, No. 9, pages 2646-2851, 1990. (Abstract)	7.
XI		Kameo, et al., "Studies on hypolipidemic agents, IV. 3-(4-(Phenylihlo) benzoyl) propionic acid derivatives", Chem. Pharm. Butl., Vol. 37, No. 5, pages 1260-1287, 1989. (Abstract)	.]
80d		Colotta, et al., "Tricyclic heteroaromatic systems: synthesis" J. Pharm. Sci., Vol. 78, No. 3, pages 239-242, 1869. (Abstract)	1
Co		Tanaka, et al., "Total synthesis of coumarinolignans, aquillochin (deemiscosin C) and deemiscosin D°, Chem. Pharm. Bull., Vol. 36, No. 10, pages 3833-3837, 1888. (Abstract)	1
m		Parmar, et al., "Synthesis of new naturally occurring 4-phenyl-2H-1-benzopyran-2-ones", Bull. Chem. Soc. Jpn., Vol. 61, No. 6, pages 2277-2279, 1988. (Abstract)	1
Jus		Colotta, et al., "The correct synthesis of 2.3-dihydro-2-sryl-4-R-[1] benzopyrano (4,3-c) pyrazola-3- ones", Tetrahedron Lotters, Vol. 28, No. 43, pages 5165-5168, 1987. (Abstract)) l
No	2	Tanaka, et al., "Yotal synthesis of daphneticin, a coumartnolignolo", Chem. Pharm. Bull., Vol. 34, No. 2 pages 628-632, 1986. (Abstract)	l J

Examiner	A Day	2/1/20
B CVBILLIEL I	Dal	1 3/9/04
Signature A	 0.00	alda
C SOMMONE IC	 	SIGRIAGI

"EXAMINER: trilled if reference considered, whether or not cholomore is in conformance with MPEP 608. Order Bno through distion if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicante unique citatian designation number (optional). 2 Applicant is to place a check morth here if English language Translation is attached.

Burden Hour Statement: This form to estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the incideduce case. Any comments on the amount of time you are required to complete this form should be cont to the Chief Information Officer, U.S. Patent and Tradement Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistent Commissions for Potents, Washington, DC 20231.

PTO/SB/088 (10.01)
Approved for use through 10/31/2002. OMB 6531-0031
U.S. Palent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
of 01 1995, no porsone are required to respond to a collection of information unless it contains to walls OMS

Compl t if Kn wn Substitute for form 14428/PTO 10/684,740 **Application Number** INFORMATION DISCLOSURE October 14, 2003 Filing Date STATEMENT BY APPLICANT Shalini Sharma First Named Inventor 1624 Group Art Urdl Sudhaker Patel (use as many sheets as necessary) Examinar Name of 10 18015-D3 Allemey Docket Number Sheet 7

		NON PATENT PUBLICATIONS	
Examiner Initials	Cto No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), (title of the litem (book, magazine, journal, serial, symposium, catalog, etc.), date, paga(s), volume-issue	7,
Six	-	Ahluwalla, et al., "Synthesis of stevenin and metanettin", Symp. Pap IUPAC int. Symp. Cham. Nat. Prod., 11th, Volume 3, pages 11-13, 1978. (Abstract)	-
Yro	۲.	Yamaguchi, "Degradation of protalignin with metallic sodium in liquid ammonis", Ringyo Shikenjo Kenkyu Hokoku, Vol 281, pagas 1-78, 1976. (Abstrad)	-
10		Okumura, et al., "Synthesis of chromone-3-carboxanilides", Chem. Pharm. Bull., Vol 22, No. 2, . pages 331-336, 1974. (Abstract)	-
go	1	Von Wacek, et al., "Synthesis of methoxylated compounds for a comparative investigation of the stability of methyl ether groups", Monatsh. Chem, Vol. 97, No. 3, pages 744-753, 1988. (Abstract)	1
King	7	wasa, et al., "The preparation of the biosynthetic precursor 3,7-dihydroxy-2, 8-dimethoxyphenthroindolizidine", J. Nat. Prod., Vol. 51, No. 1, pages 172-176, 1898. (Abstract)	F
100	\ \frac{1}{2}	Wong, et al., "Wedetolactone and coumestan derivatives as new antihopetetoxic and entiphlogistic principles", ArznelmForsch., Vol. 38, No. 5, pages 661-665, 1988. (Abstract)	-
X19		Witiak, et al., "Synthetic eci-reductiones. 3,4-Dihydroxy-2H-1-benzopyran-2-ones and their cis- and trans-4e, 5,6,7,8,8a-hexahydro diastereomers", J. Med. Chem., Vol. 31, No. 7, pages 1437-1445, 1988. (Abstract)	-
8 mg		Entzeroth, et al., "Preparation of 3- (3-indolyl) Lactic acids", Liebigs Ann. Chem., No. 2, pages 226- 230, 1983. (Abstract)	-
Kis		Bhakuni, et al., Biosynthesis of tylophorine and tylophorinine", Tetrahedron, Vol. 37, No. 2, pages 401-407, 1981. (Abstract)	-
12		Naldu, et al., "Debenzylation by nickel-aluminum alloy", J. Indian Inst. Sci., Vol. 62, No. 10, pages 177-180, 1980. (Abstract)	-
Sp		Oke, et at., "Syntheses of N-heterocyclic compounds. XXVI. Syntheses of pyrido [3,4-d] pyridazine dorivstives", Chem. Pharm. Bull., Vol. 23, No. 10, pages 2308-2317, 1875. (Abstract)	,
			Ŀ

Examiner Date Signature

EXAMINER: Initial if reference considered, whether or not distion to in conformance with MPEP 809. Draw the through distion if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark hore il English language Translation is ettached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Three will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Weshington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Weshington, DC 20231.



PTO/S8/08B (10-01)
Approved for uso through 10/31/2002. OMB 0851-0031
U.S. Palent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
At Reduction Act of 1995, no persons are required to respond to a collection of information unlass it contains a valid OMB

Under the Papers control number.

C mplete if Known Substitute for form 1448B/PTO Application Number 10/884,740 INFORMATION DISCLOSURE October 14, 2003 Filing Date Shalini Sharma First Named Inventor STATEMENT BY APPLICANT 1524 Group Art Unit Sudhaker Patel (use es meny sheete es necessary) Examinar Name of 10 Sheet B Altornay Occket Number 18015-D3

		. NON PATENT PUBLICATIONS	
Examiner Initials	CRO No.1	inctude name of the author (in CAPITAL LETTERS), (tile of the effect (when appropriate), tille of the litem (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-tesue number(a), cublisher, city and/or complex where publisher.	Τ2
800	!	Saunders, et al., "Syntheses of carbon-14-labeled prizidlioi dihydrochloride", J. Labelled Compd. Radiopharm., Vol. 22, No. 9, pages 889-881, 1985. (Abstract)	_
0		Arnoldi, et al., "Synthesis and sweet laste of some 2-phenylbenzodioxanes", J. Agric. Food Chem., Vol. 34, No. 2, pages 339-344, 1988. (Abstract)	
Sign		Winters, et al., "Synthesis and pregnancy terminating activity of pyrazolo [1,6-a] Indoles and quinolines", Eur. J. Med. Chem.—Chim. Ther., Vol. 19, No. 3, pages 215-218, 1984. (Abstract)	-
M		Herbert, et al., "Blosynthesis of phenanthroindolizidina alkaiolds: Incorporation of 2-pyrrolidin-2- ylacetophenona and benzoylacetic acid and derivatives", J. Chem. Soc., Perkin Trans. 1, No. 4., pagas 825-831, 1984, (Abstract)	-
Y		Toja, et al., "Synthesis and pregnancy terminating activity of 2-arylpyrazolo (5,1-a) isotodoles and isoquinotines", Eur. J. Med. ChemChim. Ther., Vol. 17, No. 3, pages 223-227, 1982. (Abstract)	-
D		Ahhwalla, et al., "An unambiguous synthesis of molannein", Indian J. Chem., Sect. B. Vol. 218, No. 3, pages 168-188, 1882. (Abstract)	
M		Peller, et al., "Synthesis and NMR spectra of 2,6- and 2,4-diaryl-3,7-dioxabicyclo (3.3.0] octanes", J. Chern. Soc., Perkin Trans. 1, No. 1, pages 183-190, 1982. (Abstract)	1
Of		Mangla, et al., "Synthesis of substituted 6,7-diphenyi-1,2,3,5,8,8e-hexahydroindolizines", Indian J. Chem., Sect. B, Vol. 19B, No. 11, pages 931-937, 1980. (Abstract)	-
Oct		Mangla, et al. "Synthesis of tylophorine", Tetrahadron, Vol. 36, No. 17, pages 2489-2490, 1980. (Abstract)	1
De		Ahluwelle, et al., "A novel synthesis of 4-phenylooumarins having a free hydroxyl group in the phenyl ring: synthesis of melanettin and stevenin", Heterocycles, Vol. 14, No. 9, pages 1329-1330, 1980. (Abstract)	1
Y		Chariton, et al., "The synthesis of 2-methylchromone-3-carboxylic acid", J. Heterocycl. Chem., Vol. 17, No. 3, pages 593-594, 1980. (Abstract)	_
	7		<u> </u>
Examine Signatur		Qual by 13 Considered 8/4 Of	1

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. One line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English tanguage Translation is stacked.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will very depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief information Officer, U.S. Patent and Trudement Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0551-0019
U.3. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
U.S. payind to respond to a collection of information, unless & centains a value OMB

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERC
Under the Production Act of 1895, no persons are required to respond to a collection of information unless a contains a valid OM
control number.

Complet | If Kn wn
Application Number | 10/884,740

NON PATENT PUBLICATIONS						
Examinar Iniliala	Cite No.1	include name of the author (in CAPITAL LETTERS), tills of the critics (when appropriate), file of the item (book, magazine, journel, serial, symposium, catalog, etc.), data, pagate), volume-issue numberist, miblisher, city and its country when numbered	נין			
pr.		Liu, et et, "The New Antidiabetic Drug MCC-555 Acutely 'Sensitizes Insufin Signating in Isolated Cardiomyocytes". Endocrinology, Vol 139, No. 11, pages 4531-4539, (1898).				
M		Kees, et st., "Perfivoro-N-(4-(1 H-letrazol-5-ylmsthyl) Phenyl)-akanamides. A New Class of Oral Antidiabelic Agents", Journal of Medicinal Chemistry, Vol. 32, pages 11-13, (1989).	_			
Not		Shinksi, et al. "4-(trans-4-Methylcyclohexyl)-4 Oxobutyric Acid (JTT-608). A New Class of Antidiabetic Agent", Journal of Medicinal Chemistry, Vol 41, No. 27, pages 5420-5428, (1988).				
Da		Abstract 560-P, Hodge, et al. "PN2022: Antidiabetic Efficacy and Reversal of Steatchepatitis in ob/ob Mice", Diabetes, Abstract Book 62nd Scientific Sessions, Vol. 51 Suppt. 2, page A139, June 2002.	-			
Sign		Abstract 581-P, Hodge, et al., "PN2034: Orally Active Antidiabetic Agent with a Unique Spectrum of of Activity and Enhanced Safety Profile", Diabetes, Abstract Book 62nd Scientific Sessions, Vol. 51 Suppl. 2, page A139, June 2002.	_			
M		Abstract 568-P, Lu, et al., "A Novel Antidiabelic Agent That is a Selective PPAR Modulator", Diabetes, Abstract Book 62nd Scientific Sessions, Vol 51, Suppl. 2., page A141, June 2002.	_			
M		Abstract 586-P, von Borstel, et et. "PN2034: Reversal of Insulin Resistance end Attenuation of Weight Gain in Mice on a High-Fat Diel", Diabetes, Abstract Book 62nd Scientific Sessions, Vol 51, Suppl. 2, page A145, June 2002.				
871		Poster #560, Hodge, et al., "PN2022: Antidiabetic Efficacy and Reversal of Steatohepatids in ob/ob Mice." Presentation at the 82nd Scientific Sessions, Meeting of the American Diabetes Association on June 14-18, 2002 and corresponding to Abstract \$60-P.	_			
Sp		Poster #581, Hodga, et at., "PN2034: Orally Active Antidiabetic Agent with a Unique Spectrum of Activity and Enhanced Sefety Profile", Presentation given at the 62nd Scientific Sessions, Meeting of the American Diabetes Association on June 14-18, 2002 and corresponding to Abstract 660-P.				
De		Poster #568, Lu, et al., "PN2034-A Novel Antidiabetic Agent That is a Selective PPAR Modulator", Presentation given at the 62nd Scientific Sessions, Meeting of the American Diabetes Association on June 14-18, 2002 and corresponding to Abstract 568-P.	-			
De		Poster #586, von Borstel, et at., "PN2034: Reversal of Insulin Resistance and Attenuation of Weight Gain in Mice on a High-Fat Diet", Presentation given at the 62nd Scientific Sessions, Meeting of the American Diabetes Association on June 14-18, 2002 and corresponding to Abstract 568-P.)			
Examine	,	Grad 12/2/25 Date 5/1/94	_			

^{&#}x27;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered

¹ Applicant's unique cliation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is effected.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Potent and Trademark Office. Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Pape control number.

PTO/S8/088 (10-01) Approved for use through 10/31/2022 OMB 0651-0031 U.S. Palant and Tradamark Office: U.S. DEPARTMENT OF COMMERCE ted to respond to a collection of information unless it cortains a valid OMB

Compl t if Known Substitute for form 1449B/PTO 10/884,740 Application Number INFORMATION DISCLOSURE October 14, 2003 Filing Date Shalini Sharma First Named Inventor STATEMENT BY APPLICANT 1624 Group Art Unil Sudhaker Patel (use as many sheets as necessary) Examiner Name Attorney Docket Number of 10 18015-D3 Sheet 10

Include name of the suthor (in CAPITAL LETTERS). 65e of the article (when appropriate), 60e of the litem (book, magasine, journal, serial, symposium, catalog, etc.), date, pager(s), volume-lasure manhatol exhibitors (the andior counter when ambithed pages 1002-1003, 1970. (Abstract). Weroneso, et al., "Ozonodysis of derivatices of 7-hydroxytryptopham", Gazz. Chim. Rai., Vol. 97, No. 1, pages 18-24, 1997. (Abstract). Weroneso, et al., "Ozonodysis of derivatices of 7-hydroxytryptopham", Gazz. Chim. Rai., Vol. 97, No. 1, pages 18-24, 1997. (Abstract) Kawamatsu, et al., Studies on antihyperflipMemic agents. Part 1. Synthesis and hypotipMemic activities of phenoxyphenylaikanolo acid derivatives", Arznetin. Forsch, Vol. 30, Issue 3, pages 445-459, 1980. (Abstract) Chemical Abstract DN 132:22755, also cited as W099/82520, 1949. Chemical Abstract DN 126:74845, elso cited as W099/82520, 1949. Chemical Abstract DN 117:251790, also cited as W092/12123, 1997. Chemical Abstract DN 113: 115839, elso cited as Synthetic communications, 20/5,773-81, 1990. Chemical Abstract DN 99: 122287, also cited as EP 71399, 1987. Kawamatsu et al., Arzneim. Forsh., Vol. 30 ISS3, 454-459, 1980.			NON PATENT PUBLICATIONS	
pages 1002-1003, 1970. (Abstract). Veronese, et al., "Ozonolysis of derivatices of 7-hydroxytryptophen", Gazz. Chim. Ital., Vol. 97, No. 1, pages 18-24, 1987. (Abstract) Xawamatsu, et al., Studies on antihyperlipidemic agants. Part 1. Synthesis and hypotipidemic activities of phenoxyphenylalkanotc activities.", Arzneim. Forsch, Vol. 30, Issue 3, pages 445-459, 1980. (Abstract) Chemical Abstract DN 132:22755, also cited as W099/82520, 1999. Chemical Abstract DN 128:74845, etso cited as W099/82520, 1999. Chemical Abstract DN 117:251790, also cited as Wo 92/12123, 1997. Chemical Abstract DN 113: 115839, also cited as Synthetic communications, 20/5,773-81, 1990. Chemical Abstract DN 99: 122287, also cited as EP 71399, 1987.			liem (book, magazine, journal, aerial, symposhum, catalog, etc.), dats, page(s), vokums-issus	17
pages 18-24, 1987. (Abstract) Kawamatsu, et al., Studies on antihyperlipidemic agents. Part 1. Synthesis and hypotipidemic activities of phenoxyphenylalkanoic acid derivatives", Arznelm. Forsch, Vol. 30, Issue 3, pages 445-459, 1980. (Abstract) Chemical Abstract DN 132:22755, also cited as W089/82520, 1999. Chemical Abstract DN 126:74845, also cited as J. Chem. Soc., Parkins Transactions 1, Org & Bio-Org. Chem., 21, 2803-2613, 1998. Chemical Abstract DN 117:251790, also cited as Wo 92/12123, 1997. Chemical Abstract DN 113: 115839, also cited as Synthetic communications, 20/5,773-81, 1990. Chemical Abstract DN 99: 122287, also cited as EP 71399, 1987.	Sol		Owada, et al., "Improved synthesis of tricin", Nippon Kagaku Zassht, Vol. 91, No. 10, pages 1002-1003, 1970. (Abstract).	
of phenoxyphenylalkanotc acid derivatives", Arznetm. Forsch, Vol. 30, Issue 3, pages 445-459, 1980. (Abstract) Chemical Abstract DN 132:22755, also cited as W089/82520, 1999 1 Chemical Abstract DN 128:74845, also cited as J. Chem. Soc., Parkins Transactions 1, Org & Bio-Org. Chem., 21, 2803-2813, 1998. Chemical Abstract DN 117:251790, also cited as Wo 92/12123, 1997, Chemical Abstract DN 113: 115839, also cited as Synthetic communications, 20/5,773-81, 1990. Chemical Abstract DN 99: 122287, also cited as EP 71399, 1987.	V		Veronese, et at., "Ozonolysis of derivatices of 7-hydroxytryptophen", Gazz. Chim. Ital., Vol. 97, No. 1, pages 18-24, 1987. (Abstract)	_
Chemical Abstract DN 126:74845, also cited as J. Chem. Soc., Parkins Transactions 1, Org & Bio-Org. Cham., 21, 2803-2813, 1898. Chemical Abstract DN 117:251790, also cited as Wo 92/12123, / 997. Chamical Abstract DN 113: 115839, also cited as Synthetic communications, 20/5,773-81, 1990. Chemical Abstract DN 99: 122287, also cited as EP 71399, 1987.	S		of phenoxyphenylalkenoic acid derivatives", Arzneim. Forsch, Vol. 30, issue 3, pages 445-459,	
Chemical Abstract DN 117:251790, also cited as Wo 92/12123, / qq 7 , Chemical Abstract DN 113: 115839, also cited as Synthetic communications, 20/5,773-81, 1990. Chemical Abstract DN 99: 122287, also cited as EP 71399, MB7 /	S		Chemical Abstract ON 132:22755, also clied as WO89/82520, 1999	-
Chemical Abstract DN 113: 115839, also cited as Synthetic communications, 20/5,773-81, 1990. Chemical Abstract DN 99: 122287, also cited as EP 71399, M83 /	po			-
Chemical Abstract ON 99: 122287, also cited as EP 71399, 1983	82		Chemical Abstract DN 117:251790, also died as Wo 92/12123 ₃ , 1997.	
	OF		Chamical Abstract ON 113: 115839, also cited as Synthetic communications, 20/5,773-81, 1990.	
Kawamatsu el al., Arzneim, Forsh., Vol. 30 ISS3, 454-459, 1980.	Y		Chemical Abstract ON 99: 122287, also cited as EP 71399, 1983	-
	(V)	_	Kawamatsu et al., Arzneim, Forsh., Vol. 30 ISS3, 454-459, 1980.	-
i i		_	·	-
		L		L

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw fine through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here il English language Transistion is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete that should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT GEND FEES-OR COMPLETED FORMS TO THIS ADDRESS. SEND-TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
ork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 2

Sheet 1

Complete if Known					
Application Number	10/684,740				
Filing Date	October 14, 2003				
First Named Inventor	Shalini Sharma				
Art Unit	1614				
Examiner Name	Sudhaker Patel				
Attorney Docket Number	18015-D3				

			U.S. PAT	ENT DOCUMENTS	
Examiner Initials	Cite No. 1	Document Number. Number- Kind Code ² (if known	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
SBM !		US- 4,098,816	07/04/1978	Thome, et al.	
SEEM	17	US- 4,638,094	01/20/1987	Nakai, et al.	
ZUM		US- 6,555,536	04/29/2003	Burris, et al.	
7)"		US-			
		UŞ-			

		FORI	EIGN PATENT D	OCUMENTS		
Examiner Initials	Cite No. 1	Foreign Patent Document Courby Code 3 - Number 4 - Kind Code 3 (# Immun)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	78
	7	WO 99/11255	03/11/1999			
8311	1/	WO 99/20275	04/29/1999			
COM)	7	WO 01/40170	06/07/2001			
WAN		DE 2 309 986	08/29/1974			
7)						_
						-

Considered Signature

Date

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional), ² See Kinds Codes of USPTO Patent Documents at www.usplo.qov or MPEP 901.04. ³ Enter Office that issued the document, by the two-latter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Surden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Examiner

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449B/PTO 10/684,740 **Application Number** INFORMATION DISCLOSURE October 14, 2003 Filing Date Shalini Sharma First Named Inventor STATEMENT BY APPLICANT 1614 **Group Art Unit** Examiner Name Sudhaker Patel (use as many sheets as necessary) of 2 Attorney Docket Number 18015-D3 Sheet 2

NON PATENT PUBLICATIONS								
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2					
DU		Witiak, et al., "Synthesis of Ethyl 6-Substituted-Chroman-and-Chromone-2-carboxylates. A Comparative Structure-Activity Study Employing the 6-Phenyl and Phenoxy Analogs in the Triton Hyperlipidemic Rat Model", Journal Medical Chemistry, Vol. 18, No. 9, Pages 934-942, 1975.						
)								
			_					
		·						
Examine	r	Date Considered 8 30 6	5					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.